TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03024905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Village meeting and travel vouchers
Description: The interventions are:~1. Village meetings by community health workers to educate women and their families about safe birthing.~2. Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Village meeting and travel vouchers
Description: The interventions are:~1. Village meetings by community health workers to educate women and their families about safe birthing.~2. Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Village meeting and travel vouchers
Description: The interventions are:~1. Village meetings by community health workers to educate women and their families about safe birthing.~2. Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Village meeting and travel vouchers
Description: The interventions are:~1. Village meetings by community health workers to educate women and their families about safe birthing.~2. Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Birth kit with misoprostol
Description: Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Birth kit with misoprostol
Description: Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Birth kit with misoprostol
Description: Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Birth kit with misoprostol
Description: Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).
Study: NCT02708563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate intubation
Description: Infants that are not vigorous at delivery will receive immediate tracheal suctioning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate resuscitation
Description: Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
Study: NCT02855697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg taken twice daily, equivalent to a total daily dose of 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 20mg dose of cediranib was selected for this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: 1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
Study: NCT04916093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: Galvus 50 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg
Description: Januvia 100mg oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 1000 Mg Oral Tablet
Description: Glucophage 1000 mg oral tablets
Study: NCT03028727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Scaling and root planing
Description: Procedure of scaling and root planing at day 0 and at 1 week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic Scaling and root planing
Description: Procedure of scaling and root planing at day 0 and at 1 week
Study: NCT01505777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics (Medirac)
Description: 30/mosapride 15mg three times a day, P.O. 4week
Study: NCT03028727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser irradiation
Description: Procedure of scaling and root planing and application of 980 nm diode laser at day 0 and at 1 week
Study: NCT04193436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919 25 mg
Description: PF-06835919 in 25 mg oral tablet will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919 25 mg
Description: PF-06835919 in 25 mg oral tablet will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919 25 mg
Description: PF-06835919 in 25 mg oral tablet will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919 25 mg
Description: PF-06835919 in 25 mg oral tablet will be administered on Day 1
Study: NCT00620295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m\^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m\^2) on day 1 and day 8 of a 21 day cycle.
Study: NCT05499845

Intervention type: DIAGNOSTIC_TEST
Intervention: butanol threshold test and smell identification tests
Description: no additional intervention
Study: NCT01505777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics (Medirac) placebo/mosapride placebo
Description: three times a day, P.O. 4week
Study: NCT02594319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Study: NCT02594319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary incentives

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self monitoring
Study: NCT04131166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: A Mediterranean-type diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: A Mediterranean-type diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, ketogenic diet
Description: A low-carbohydrate, ketogenic diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, ketogenic diet
Description: A low-carbohydrate, ketogenic diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: A low-fat diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: A low-fat diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.

Intervention type: OTHER
Group type: OTHER
Intervention: Annual follow-up testing for 5 years
Description: Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual follow-up testing for 5 years
Description: Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual follow-up testing for 5 years
Description: Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual follow-up testing for 5 years
Description: Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual follow-up testing for 5 years
Description: Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual follow-up testing for 5 years
Description: Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual follow-up testing for 5 years
Description: Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
Study: NCT02404727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cup fixation
Description: All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cup fixation
Description: All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avantage® Cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avantage® Cup
Study: NCT00964886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desipramine hydrochloride
Description: desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: benztropine mesylate 0.125 mg daily
Description: benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desipramine hydrochloride
Description: desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
Study: NCT03775434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: B244
Description: B244 suspension in 30ml/bottle
Study: NCT02594319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self monitoring
Study: NCT04394598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dendrobium Huoshanense Granules
Description: 3g tid per day for 5weeks
Study: NCT05052177

Intervention type: DEVICE
Intervention: Edge to edge repair in systemic tricuspid valve regurgitation
Description: Edge to edge repair of severe tricuspid regurgitation on a right systemic ventricle with a Mitraclip device.
Study: NCT04394598

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic Radiation
Description: 50Gy/25Fx
Study: NCT01828632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Physical Therapy
Description: Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
Study: NCT01603134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 300 mg tablet once a day
Study: NCT04394598

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Pelvic Radiation
Description: 50Gy/25Fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625mg/m2 bid Monday-Friday per week
Study: NCT01783964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Elacytarabine
Description: Single intravenous administration
Study: NCT03231280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SB-061
Description: delivered via intra-articular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered via intra-articular injection
Study: NCT01341054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouthwash with Chamomilla
Description: The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouthwash with Chamomilla
Description: The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouthwash with Chamomilla
Description: The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral care protocol
Description: The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
Study: NCT03282825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle.
Study: NCT01854398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP group
Description: Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-CPAP group
Description: Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
Study: NCT02405728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Centrally inserted central catheters (CICCs)
Description: Randomization between two well established clinical routine vascular access devices

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripherally inserted central catheters (PICCs)
Description: Randomization between two well established clinical routine vascular access devices
Study: NCT03847792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group DB/Dexamethasone-Bupivacaine
Description: The patient were received an intra-articular injection of 18ml bupivacaine 0.25% added to 8mg dexamethasone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group FB /Fentanyl-Bupivacaine
Description: The patient were received an intra-articular injection of 1 ug/kg fentanyl added to 18ml of 0.25% bupivacaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group PB/Placebo-Bupivacaine
Description: Patients were received an intra-articular injection of 2ml isotonic saline added to 18ml of 0.25% bupivacaine.
Study: NCT00652327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)
Description: ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double Statin (simvastatin, atorvastatin, or pravastatin)
Description: simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
Study: NCT04767243

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: open flap debridement and filled with A-PRF ( Advanced platelet rich fibrin)
Description: After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement and filled with Bioactive glass (Perioglas®)
Description: After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF
Description: After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
Study: NCT04677634

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: ISOThrive Prebiotic Nectar
Description: The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily.
Study: NCT04394598

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 625mg/m2 bid Monday-Friday per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g tid per day for 5weeks
Study: NCT00683228

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
Study: NCT01019161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152
Description: 100mg Lyophile, 5mL Diluent IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C14 AZD1152
Description: radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
Study: NCT02797834

Intervention type: PROCEDURE
Intervention: Endometrial fluid collection
Study: NCT03586310

Intervention type: DEVICE
Group type: OTHER
Intervention: ear-EEG
Description: soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.

Intervention type: DEVICE
Group type: OTHER
Intervention: ear-EEG
Description: soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
Study: NCT00496769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Tablets, oral, 81-324 mg, once daily, up to 156 weeks
Study: NCT01056692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC000459
Description: Capsules twice daily for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules twice daily for 15 days
Study: NCT00004862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate